Optinose reports Q1 XHANCE revenue $14.9M (+26% YoY); sees peak >$300M

OptiNose, Inc.

Q1 2024 XHANCE net revenue $14.9M, up ~26% vs Q1 2023.
FDA approved XHANCE as first drug treatment for chronic sinusitis without nasal polyps.
Expects peak XHANCE net revenue >$300M; positive GAAP ops income by FY2025.
Leveraging 75 sales territories to target 3M patients; limited incremental spend.
Plans to use specialty pharmacy hub to improve prescription fill and reimbursement.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OptiNose, Inc. reported the three months ended March 31, 2024 results: revenue $14.9 million. Guidance initiated.

Period: the three months ended March 31, 2024
Revenue: $14.9 million
Guidance: initiated
Result: preliminary results

Exact text from the filing

the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31, 2024

View on SEC.gov

492 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001494650-24-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.